CA3113172A1 - Screen for compound that prevents protein oxidation based on comparison with l-tryptophan - Google Patents

Screen for compound that prevents protein oxidation based on comparison with l-tryptophan

Info

Publication number
CA3113172A1
CA3113172A1 CA3113172A CA3113172A CA3113172A1 CA 3113172 A1 CA3113172 A1 CA 3113172A1 CA 3113172 A CA3113172 A CA 3113172A CA 3113172 A CA3113172 A CA 3113172A CA 3113172 A1 CA3113172 A1 CA 3113172A1
Authority
CA
Canada
Prior art keywords
antibody
oxidation
protein
antibodies
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3113172A
Other languages
English (en)
Inventor
Sreedhara Alavattam
Mary MALLANEY
Parbir GREWAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA3113172A1 publication Critical patent/CA3113172A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Lubricants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3113172A 2013-03-13 2014-03-13 Screen for compound that prevents protein oxidation based on comparison with l-tryptophan Abandoned CA3113172A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780845P 2013-03-13 2013-03-13
US61/780,845 2013-03-13
US201361909813P 2013-11-27 2013-11-27
US61/909,813 2013-11-27
CA2904166A CA2904166C (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2904166A Division CA2904166C (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Publications (1)

Publication Number Publication Date
CA3113172A1 true CA3113172A1 (en) 2014-10-02

Family

ID=51625442

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3113172A Abandoned CA3113172A1 (en) 2013-03-13 2014-03-13 Screen for compound that prevents protein oxidation based on comparison with l-tryptophan
CA2904166A Active CA2904166C (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2904166A Active CA2904166C (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Country Status (23)

Country Link
EP (1) EP2968466B1 (OSRAM)
JP (3) JP6389236B2 (OSRAM)
KR (1) KR102237885B1 (OSRAM)
CN (2) CN110075293A (OSRAM)
AU (3) AU2014243700B2 (OSRAM)
CA (2) CA3113172A1 (OSRAM)
DK (1) DK2968466T3 (OSRAM)
ES (1) ES2688895T3 (OSRAM)
HR (1) HRP20181504T1 (OSRAM)
HU (1) HUE039948T2 (OSRAM)
IL (2) IL269947B (OSRAM)
LT (1) LT2968466T (OSRAM)
MX (2) MX369671B (OSRAM)
MY (2) MY199135A (OSRAM)
NZ (1) NZ711566A (OSRAM)
PL (1) PL2968466T3 (OSRAM)
PT (1) PT2968466T (OSRAM)
RS (1) RS57813B1 (OSRAM)
RU (1) RU2707092C2 (OSRAM)
SG (2) SG10201705525VA (OSRAM)
SI (1) SI2968466T1 (OSRAM)
WO (1) WO2014160495A1 (OSRAM)
ZA (2) ZA201506876B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2968467T1 (sl) * 2013-03-13 2020-11-30 F. Hoffmann-La Roche Ag Pripravki z zmanjšano oksidacijo
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN109415440B (zh) 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
WO2019073996A1 (ja) * 2017-10-13 2019-04-18 株式会社タムラテコ 有害物処理方法およびオゾン発生装置
SG11202100601TA (en) * 2018-08-08 2021-02-25 Genentech Inc Use of tryptophan derivatives and l-methionine for protein formulation

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2095873A1 (en) 1996-08-30 2009-09-02 Upfront Chromatography A/S Isolation of immunoglobulins
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
JP2005524601A (ja) * 2000-09-15 2005-08-18 ザ スクリップス リサーチ インスティテュート 抗体による過酸化水素およびスーパーオキシド生成に関する方法および組成物
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
US7682608B2 (en) * 2001-08-29 2010-03-23 Chugai Seiyaku Kabushiki Kaisha Stabilized preparations containing antibody
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
AU2004205898B2 (en) 2003-01-17 2009-11-19 The Research Foundation Of State University Of New York Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2526398C (en) 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
US7709604B2 (en) * 2003-12-18 2010-05-04 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
EP1986674A4 (en) * 2006-02-13 2009-11-11 Nektar Therapeutics PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME
CN101438158A (zh) * 2006-03-06 2009-05-20 阿穆尼克斯股份有限公司 遗传包和其应用
JP2007319124A (ja) * 2006-06-02 2007-12-13 Nippon Tablet Kk 健康食品
DK2118279T3 (en) * 2007-01-16 2018-02-26 Ipintl Llc HIS UNKNOWN COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME
WO2009145982A1 (en) * 2008-04-01 2009-12-03 Antipodean Pharmaceuticals, Inc. Compositions and methods for skin care
NZ591025A (en) * 2008-08-21 2013-01-25 Alvine Pharmaceuticals Inc Formulation for oral administration of proteins
MX2011002372A (es) * 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
CA2736864C (en) 2008-09-19 2020-10-13 Pfizer Inc. Stable liquid antibody formulation
MY184736A (en) * 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
RU2447448C1 (ru) * 2010-08-30 2012-04-10 Государственное образовательное учреждение высшего профессионального образования "Оренбургский государственный университет" Способ стабилизации антител в водных растворах
WO2012170883A1 (en) * 2011-06-09 2012-12-13 Discovery Pharma Consulting, Llc Antihistamines combined with dietary supplements for improved health
WO2013001044A1 (en) * 2011-06-28 2013-01-03 Leukocare Ag Method for preventing the unfolding of a (poly) peptide and/or inducing the (re- ) folding of a (poly) peptide

Also Published As

Publication number Publication date
DK2968466T3 (en) 2018-10-22
MX2015011432A (es) 2016-04-27
ES2688895T3 (es) 2018-11-07
AU2019202464B2 (en) 2020-12-10
AU2014243700B2 (en) 2019-01-24
NZ751543A (en) 2020-09-25
CN110075293A (zh) 2019-08-02
JP2016520521A (ja) 2016-07-14
IL269947B (en) 2022-08-01
KR102237885B1 (ko) 2021-04-07
HRP20181504T1 (hr) 2018-11-02
BR112015022484A2 (pt) 2017-07-18
LT2968466T (lt) 2018-10-10
AU2019202464A1 (en) 2019-05-02
RS57813B1 (sr) 2018-12-31
IL269947A (OSRAM) 2019-12-31
NZ711566A (en) 2020-06-26
RU2015143548A (ru) 2017-04-20
JP2020164531A (ja) 2020-10-08
PT2968466T (pt) 2018-10-22
HUE039948T2 (hu) 2019-02-28
ZA201906057B (en) 2022-04-28
RU2707092C2 (ru) 2019-11-22
CA2904166A1 (en) 2014-10-02
KR20150130397A (ko) 2015-11-23
SI2968466T1 (sl) 2018-10-30
EP2968466B1 (en) 2018-07-25
CN104968362A (zh) 2015-10-07
WO2014160495A1 (en) 2014-10-02
HK1211219A1 (en) 2016-05-20
CA2904166C (en) 2021-05-18
SG11201507043SA (en) 2015-10-29
AU2014243700A1 (en) 2015-10-08
MX369671B (es) 2019-11-15
JP6389236B2 (ja) 2018-09-12
ZA201506876B (en) 2019-12-18
EP2968466A4 (en) 2016-10-26
MY174679A (en) 2020-05-06
MX2019013560A (es) 2020-01-20
JP2018150317A (ja) 2018-09-27
PL2968466T3 (pl) 2018-11-30
MY199135A (en) 2023-10-17
IL240933B (en) 2019-10-31
EP2968466A1 (en) 2016-01-20
IL240933A0 (en) 2015-11-30
SG10201705525VA (en) 2017-08-30
AU2021201366A1 (en) 2021-03-18
CN104968362B (zh) 2018-12-14

Similar Documents

Publication Publication Date Title
US20260060959A1 (en) Formulations with reduced oxidation
AU2019202464B2 (en) Formulations with reduced oxidation
US20200246465A1 (en) Use of tryptophan derivatives for protein formulations
US10653779B2 (en) Formulations with reduced oxidation
JP2019167349A (ja) 酸化還元製剤
JP2016520521A5 (OSRAM)
NZ751543B2 (en) Formulations with reduced oxidation
HK1211219B (zh) 氧化降低的配制剂
BR112015022484B1 (pt) Formulação líquida, seu método de produção, e método para impedir a oxidação de uma proteína na dita formulação líquida

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210323

FZDE Discontinued

Effective date: 20230602